Phase 2 N=20 A Study in Participants With Acute Leukemia
Leukemia
Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=116 Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants
Phase 2 N=35 S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Leukemia
Primary: Complete Remission — 52 percentage of participants
N/A N=589 Latin American Real-world Study in Acute Leukemia
Acute Myeloid Leukemia · Acute Lymphoid Leukemia
Primary: Number of Participants According to Health Insurance Type — 265; 44; 253; 27 Participants
Phase 2 N=120 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: 3-Year Event-Free Survival (EFS) — 68 Participants
N/A N=109 Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy
Leukemia
Primary: Mean Number of RBC Units Transfused During Initial 5 Months of Treatment — 10.63; 13.11 PRBC Units
Phase 3 N=498 Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Lymphoblastic Leukemia, Acute
Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants
Phase 2 N=79 S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Leukemia
Primary: Continuous Complete Remission at 1 Year — 21 participants
Phase 1 N=23 Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
Acute Myeloid Leukemia · Essential Thrombocythemia
Primary: Recommended Phase 2 Dose of LY573636-Sodium in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Essential Thrombocythemia (ET)
Phase 2 N=54 Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: Number of Participants With Morphological Complete Response Rate — 27; 20 Participants
Phase 2 N=15 Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Phase 3 N=108 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Childhood Acute Promyelocytic Leukemia With PML-RARA · Myeloid Neoplasm
Primary: Event-free Survival (EFS) — 95.4; 82.9 Percentage of participants
Phase 2 N=45 Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory Philadelphia Positive B-precursor ALL
Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…
Phase 2 N=78 S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Leukemia
Primary: Continuous Complete Remission at 3 Years — 74 percentage of participants
Phase 2 N=55 Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase
Acute Lymphoblastic Leukemia
Primary: Pharmacokinetics ASNase Activity >100 U/L at 14 Days — 92.5 percentage of patients
Phase 3 N=111 Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Leukemia, Acute Lymphoblastic
Primary: Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) — 7.4; NA months — p=< 0.001
Phase 2 N=69 Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
Acute Leukemias
Primary: Rate of Complete Remission (CR) — 0; 0 Participants
Phase 2 N=31 Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Phase 2 N=300 Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Acute Undifferentiated Leukemia · B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I) — 30 mg
N/A N=100 Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute
Primary: Survial Rate at 30 Days — 100; 97 percentage of participants
Phase 2 N=29 Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Phase 2 N=41 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
Phase 2 N=37 Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Primary: Recommended Phase II Dose — 5 mg/m^2
Phase 2 N=37 Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Phase 2 N=57 Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years
Phase 2 N=16 Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
B-Cell Acute Lymphoblastic Leukemia, Adult
Primary: Best Overall Response Rate (ORR) — 6; 0; 1; 0 Participants
Phase 2 N=10 Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia
Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants
Phase 2 N=148 A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Acute Leukaemia
Primary: Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) as a Measure of Safety and Tolerability. — 72; 66; 24; 14 Participants
Phase 2 N=73 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Phase 1 N=24 AC220 for Children With Relapsed/Refractory ALL or AML
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants